News

Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to ...
13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know
In the preceding three months, 13 analysts have released ratings for ACADIA Pharmaceuticals ACAD, presenting a wide array of ...
Investing2d
Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital - Investing.com
Investing.com - RBC Capital raised its price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $38.00 from $26.00 on Monday, while maintaining an Outperform rating on the stock.The company ...
ACADIA Pharmaceuticals (ACAD) Receives a Buy from Canaccord Genuity
Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.
Cantor Fitzgerald Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)
Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.
Investing29d
Acadia Pharmaceuticals hires new SVP for Rare Disease unit
SAN DIEGO - Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a $3.71 billion market cap pharmaceutical company with excellent financial health according to InvestingPro analysis, has announced the ...
Acadia Pharmaceuticals Gets Another Court Win for Parkinson's Treatment
Acadia Pharmaceuticals has scored a second court win in less than a month that protects patents for its Parkinson's Disease treatment Nuplazid. The biopharmaceutical company said Monday that a federal ...
Investing29d
Acadia Pharmaceuticals hires new SVP for Rare Disease unit
SAN DIEGO - Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a $3.71 billion market cap pharmaceutical company with excellent financial health according to InvestingPro analysis, has announced the ...